The latest Business updates from the science industry
by Gwyneth Astles Eppendorf AG Reports Positive First Half-Year in 2019
The globally active Eppendorf Group charted a strong fi rst half-year in 2019 with a signifi cant surge in Group sales to €378.5 million (prior year: €335.6 million). This positive development corresponds to an organic increase in sales of 12.8% (8.8% in local currencies). All of the company’s market regions contributed to this very good development, but sales growth of around 20% in China and 15% in North America was particularly remarkable.
Owing to extensive and continuous investments, income from operations (EBIT) declined slightly during the fi rst half of the year to €66.7 million compared with last year (prior year: €67.3 million), amounting to an EBIT margin of 17.6% (prior year: 20.0%).
“Eppendorf profi ted from a generally good market environment during the fi rst half of 2019,” explained Thomas Bachmann, President & CEO of Eppendorf AG. “Moreover, we see that Eppendorf’s strategic reorientation is taking effect and enabling additional growth.” This was particularly noteworthy, Bachmann added, because Eppendorf’s employees at all its facilities around the world had succeeded in accelerating the company’s growth course once again despite the additional effort required by the changes at Eppendorf.
“We would like to extend our sincere thanks to all our employees worldwide for this extraordinary commitment,” he said.
Thanks to the very strong development during the fi rst half-year and the positive market environment, Eppendorf assumes that it will reach its ambitious growth targets for the entire year and that the company will once again grow faster than the market.
As part of the targeted implementation of its company strategy, Eppendorf is continuing to invest heavily in new product and service solutions as well as in digitalisation and new business models. This also applies to expansions in production capacity and infrastructure at its German sites in Hamburg,
Thomas Bachmann, President & CEO of Eppendorf AG.
Oldenburg in Holstein, Leipzig and Jülich as well as at the Enfi eld site, USA. These construction projects represent important efforts in the company’s push for further profi table and sustainable growth. In view of the higher costs planned for the infrastructure measures and given comparable exchange rates for the entire year of 2019, the company assumes that EBIT in 2019 will remain at or around the prior-year level of €153.7 million.
More information online:
ilmt.co/PL/5k9g 50135pr@reply-direct.com
Cytena Founds Subsidiary in Taiwan
Cytena, the specialist for single-cell technologies, is continuing its growth with the establishment of its subsidiary Cytena Bioprocess Solutions in Taiwan. Cytena Bioprocess Solutions is developing an innovative technology, which enables considerable reductions in time and increases in effi ciency for cell line development.
“With the new R&D focused company, we want to further strengthen our global market position and open up new application areas and target markets. Our team in Taipei will enable us to be even closer to our Asian partners and use local R&D and production resources,” said Dr Jonas Schoendube, CEO of Cytena in Germany.
Cytena Bioprocess Solutions will focus on providing bioprocess solutions for pharmaceutical companies and leading research institutes. These solutions are based on an innovative microbioreactor called
C.Bird. The
C.Bird is the fi rst microbioreactor to combine early stage cell culture screening,
monitoring and optimisation. This enables customers to save several weeks of cell line development by selecting the right clones or cell cultures very early in the process.
Jonas Schoendube is particularly pleased about the strong team on-site in Taiwan: “With Dr Charles Tsai, CEO of Cytena Bioprocess Solutions, and Elbert Chen, CFO of Cytena Bioprocess Solutions, we have found partners who will use their expertise to drive the company forward.“
“It is fantastic to be working with Cytena to bring to market a new leading- edge technology for cell line development. By establishing a site in Asia, Cytena will build new connections and enable fast delivery of our products to our global customers,” said Charles Tsai.
50232pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124
